PrEP Update

How generic medicines are helping reshape pre-exposure prophylaxis (PrEP)

Presenters include Robert Pilarski, MD; Michael Fanous, PharmD, RPh, and Anne-Marie White, PharmD

If you already have an account, please log in.

Log In

Create Account and Register for Event

PrEP Update

How generic medicines are helping reshape pre-exposure prophylaxis (PrEP)

Thursday, March 08, 2018
8:00 PM – 9:30 PM EST

Learning Objectives

  1. Describe the efficacy of oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) in providing protection against the acquisition of HIV infection
  2. Determine how to identify an at-risk person who would be an appropriate candidate for PrEP
  3. Explore best practices for the consistent and correct use of PrEP as an effective strategy to help prevent the sexual transmission of HIV
  4. Discuss the importance of adherence to maximize PrEP efficacy
  5. Understand the fundamental principles and benefits of bioequivalence testing
  6. Review the cost and comparative bioavailability studies between generic and brand name FTC/TDF

Reminders will be sent to your inbox 48, 24 and 2 hours before the event.

Please fill out your information below to create an account and register for this event. All fields are required unless otherwise marked.

Your password must be at least 8 characters long and have: one number, one upper case letter and one lower case letter.
 I accept that this site uses cookies to track my activity related to this site in order to provide a better browsing experience in accordance with its Privacy Policy.
 I would like to receive future communications from Teva Canada. (optional)

Following attendance of the live webinar, you will be required to submit an online program evaluation to complete your accreditation. Your letter of attendance will then immediately be available for download and a copy will be emailed to you.

This Group Learning program has been certified by the College of Family Physicians of Canada and the Ontario and Quebec Chapters for up to 1.5 Mainpro+ credits.

The Canadian Council on Continuing Education in Pharmacy has accredited this program for 1.5 CEUs.
Activity number: 1160-2017-2241-L-P | Date accredited: Dec. 8, 2017 | Accreditation expiry date: Dec. 8, 2018

Cette activité de formation continue a été accréditée par l’OPQ qui accordera 1,0 UFC aux pharmaciens qui y auront assisté.
Numéro d’activité : 1820 | Date d’accréditation : 24 janvier 2018 | Date d’expiration de l’accréditation : 24 janvier 2019

This program is supported in part by an educational grant from Teva Canada.